Cardioprotection by Aliskiren

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1039021

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cardiovascular disease is the leading cause of death in Australia. Aliskiren is the first renin inhibitor-type drug to be approved for clinical use for treatment of hypertension. The aim of this project is to evaluate the effectiveness of aliskiren for the treatment of heart attack and heart failure, as compared to existing therapies. Aliskiren may potentially replace or complement current therapies, thereby reducing death and improving health and economic benefits for the community.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Postgraduate Scholarships

Funding Amount: $74,263.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cardiology (incl. Cardiovascular Diseases)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bradykinin | cardiac hypertrophy | cardioprotection | cardiovascular disease | cardiovascular pharmacology | heart attack | heart failure | kallikrein-kinin system | myocardial ischaemia | renin-angiotensin system (RAS)

Related Links